Patents Assigned to Tanabe Pharma Corporation
-
Publication number: 20180100012Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity arid few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.Type: ApplicationFiled: April 27, 2016Publication date: April 12, 2018Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Motonori HASHIMOTO, Toshihide YAMASHITA
-
Publication number: 20180017573Abstract: The polynucleotide construct of (1) or (2) below is used to perform ribosome display, CIS display and/or mRNA display in order to screen a Fab against an antigen of interest: (1) a polynucleotide construct which monocistronically comprises a ribosome-binding sequence, Fab first chain-coding sequence, linker peptide-coding sequence, Fab second chain-coding sequence and scaffold-coding sequence in this order, and further comprises at its 3?-end a structure necessary for maintaining a complex with the Fab encoded by itself; and (2) a polynucleotide construct which comprises a Fab first chain-expressing cistron and a Fab second chain-expressing cistron each containing a ribosome-binding sequence, a Fab first chain-coding sequence or Fab second chain-coding sequence, and a scaffold-coding sequence in this order, the first Fab-expressing cistron further comprising at its 3?-end a ribosome stall sequence, said Fab second chain-expressing cistron further comprising at its 3?-end a structure necessary for maintainingType: ApplicationFiled: September 1, 2017Publication date: January 18, 2018Applicants: Mitsubishi Tanabe Pharma Corporation, The University of TokyoInventors: Yasuhiro FUJINO, Risako FUJITA, Kouichi WADA, Kotomi ODA, Takuya UEDA, Yoshihiro SHIMIZU, Takashi KANAMORI
-
Patent number: 9783522Abstract: Provided is a compound superior in an autotaxin inhibitory action and the like, effective as a prophylactic or therapeutic drug for diseases involving ATX. The present invention relates to a compound represented by the following formula (I): [wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.Type: GrantFiled: April 24, 2015Date of Patent: October 10, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Taichi Takahashi, Akinori Umino, Daisuke Iijima, Hisayuki Takamatsu
-
Publication number: 20170273949Abstract: It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof.Type: ApplicationFiled: March 19, 2015Publication date: September 28, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hideaki HARA, Masamitsu SHIMAZAWA, Tomomi MASUDA
-
Publication number: 20170267633Abstract: The present invention provides novel crystal forms of arylalkylamine compounds. Specifically, the novel crystal forms of 4-(3S-(1R-(1-naphthyl)ethylamino)pyrrolidin-1-yl)phenylacetic acid have excellent stability and therefore are useful as pharmaceutical ingredients. The present invention also provides industrially advantageous processes for producing the arylalkylamine compounds.Type: ApplicationFiled: March 30, 2017Publication date: September 21, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hiroshi MIYAZAKI, Takao KOMASAKA, Joji TSURUMOTO, Takeshi UEMURA, Yuuji MORITA
-
Patent number: 9758578Abstract: An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.Type: GrantFiled: December 26, 2014Date of Patent: September 12, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yasuhiro Fujino, Tsutomu Yoshikawa, Hiroshi Ochi
-
Patent number: 9753040Abstract: The polynucleotide construct of (1) or (2) below is used to perform ribosome display, CIS display and/or mRNA display in order to screen a Fab against an antigen of interest: (1) a polynucleotide construct which monocistronically comprises a ribosome-binding sequence, Fab first chain-coding sequence, linker peptide-coding sequence, Fab second chain-coding sequence and scaffold-coding sequence in this order, and further comprises at its 3?-end a structure necessary for maintaining a complex with the Fab encoded by itself; and (2) a polynucleotide construct which comprises a Fab first chain-expressing cistron and a Fab second chain-expressing cistron each containing a ribosome-binding sequence, a Fab first chain-coding sequence or Fab second chain-coding sequence, and a scaffold-coding sequence in this order, the first Fab-expressing cistron further comprising at its 3?-end a ribosome stall sequence, said Fab second chain-expressing cistron further comprising at its 3?-end a structure necessary for maintainingType: GrantFiled: November 30, 2011Date of Patent: September 5, 2017Assignees: Mitsubishi Tanabe Pharma Corporation, The University of TokyoInventors: Yasuhiro Fujino, Risako Fujita, Kouichi Wada, Kotomi Oda, Takuya Ueda, Yoshihiro Shimizu, Takashi Kanamori
-
Patent number: 9751938Abstract: Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM.Type: GrantFiled: May 9, 2016Date of Patent: September 5, 2017Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Toshihide Yamashita, Takekazu Kubo
-
Patent number: 9751846Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: GrantFiled: July 8, 2016Date of Patent: September 5, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
-
Patent number: 9725508Abstract: An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.Type: GrantFiled: December 26, 2014Date of Patent: August 8, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yasuhiro Fujino, Tsutomu Yoshikawa, Hiroshi Ochi
-
Publication number: 20170190697Abstract: The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; R1 represents an optionally substituted alkyl group or the like; R2 represents a halogen atom or the like; and R3 is an alkyl group substituted with an optionally substituted aryl group or the like, and R4 is a hydrogen atom or the like; or R3 and R4 are terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 28, 2015Publication date: July 6, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yasuo YAMAMOTO, Atsushi SATO, Kenji MOROKUMA, Hiroaki SHITAMA, Takashi ADACHI, Masahiko MIYASHIRO
-
Patent number: 9657043Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.Type: GrantFiled: April 23, 2013Date of Patent: May 23, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
-
Patent number: 9655852Abstract: The present invention is directed to a tablet containing a 1-(?-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound in high drug loading, in particular, containing the compound ranging from 30 to 95% by weight of tablet and pharmaceutically acceptable additives.Type: GrantFiled: April 20, 2016Date of Patent: May 23, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Masaaki Sugimoto, Hajime Kinoshita, Takayuki Tokuda
-
Patent number: 9643920Abstract: The present invention provides crystal forms A and B of 4-(3S-(1R-(1-naphthyl)ethylamino)pyrrolidin-1-yl)phenylacetic acid having excellent stability and use as pharmaceutical ingredients. The present invention also provides industrially advantageous processes for producing these crystalline compounds.Type: GrantFiled: September 5, 2014Date of Patent: May 9, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hiroshi Miyazaki, Takao Komasaka, Joji Tsurumoto, Takeshi Uemura, Yuuji Morita
-
Publication number: 20170081412Abstract: Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.Type: ApplicationFiled: March 16, 2015Publication date: March 23, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Roland NEWMAN, Steve GRANGER, Michael LYMAN, Dragan GRABULOVSKI, Richard WOODS, Michela SILACCI, Wenjuan ZHA, Isabella ATTINGER-TOLLER
-
Publication number: 20170050950Abstract: The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.Type: ApplicationFiled: August 29, 2016Publication date: February 23, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kunio SARUTA, Norimitsu HAYASHI, Osamu SAKURAI, Hiroaki SAWAMOTO, Eri OOBOKI
-
Patent number: 9572806Abstract: The invention provides a solid preparation which does not undergo the delay of elution of the active ingredient even after long-term storage. The solid preparation independently contains a teneligliptin-containing part containing teneligliptin or a salt thereof, or a solvate of teneligliptin or the salt thereof, in an amount 1.5- to 10-fold larger than that desired for the solid preparation.Type: GrantFiled: December 17, 2010Date of Patent: February 21, 2017Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Yasuaki Obayashi, Shinichiro Yasui, Hidaka Abe
-
Publication number: 20170044133Abstract: Provided is a compound superior in an autotaxin inhibitory action and the like, effective as a prophylactic or therapeutic drug for diseases involving ATX. The present invention relates to a compound represented by the following formula (I): [wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.Type: ApplicationFiled: April 24, 2015Publication date: February 16, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Taichi TAKAHASHI, Akinori UMINO, Daisuke IIJIMA, Hisayuki TAKAMATSU
-
Publication number: 20170044115Abstract: This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 23, 2015Publication date: February 16, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hideki USHIROGOCHI, Wataru SASAKI, Yuichi ONDA, Ryo SAKAKIBARA, Fumihiko AKAHOSHI
-
Patent number: 9556159Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R1 is a cycloalkyl group or an alkyl, R22 is an optionally substituted aryl and the like, R is a lower alkyl group, R3, R4, R5 and R6 are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 13, 2013Date of Patent: January 31, 2017Assignees: Mitsubishi Tanabe Pharma Corporation, Shanghai Pharmaceuticals Holding Co., Ltd.Inventors: Toru Iijima, Yoichi Takahashi, Miki Hirai, Hiroshi Sugama, Yuko Togashi, Jingkang Shen, Guangxin Xia, Huixin Wan